RxDoctor Payments Data

Julia McAree, PA

Physician Assistant · Westland, MINPI 1053926899

Payments from drug & device makers

$10,854in general payments, 2019–2025

Across 509 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Sun Pharmaceutical Industries Inc.$978
  • Lilly USA, LLC$660
  • Sanofi$624
  • Pfizer$528
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$10,42496%
  • Education$4314%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,854 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$81,248
Medicare patients
203
Services billed
1,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$65,770
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$48,382
AdbryTralokinumab-Ldrm12$47,821
JardianceEmpagliflozin52$46,847
EliquisApixaban42$43,380
TrulicityDulaglutide23$37,502
FarxigaDapagliflozin Propanediol41$37,049
MounjaroTirzepatide32$34,320
UbrelvyUbrogepant23$23,431
RybelsusSemaglutide15$17,513
XareltoRivaroxaban22$16,993
EntrestoSacubitril/Valsartan22$15,497
JanuviaSitagliptin Phosphate22$12,975
KerendiaFinerenone15$12,497
LinzessLinaclotide22$11,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$403$83,28383 claims
Lilly USA, LLCTrulicity, Mounjaro$660$71,82255 claims
GSKTrelegy Ellipta$321$48,38248 claims
LEO Pharma Inc.Adbry$180$47,82112 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,730$47,44256 claims
Boehringer IngelheimJardiance$177$46,84752 claims
PfizerEliquis$528$43,38042 claims
AbbVieUbrelvy, Linzess$1,466$35,19745 claims
Johnson & JohnsonXarelto$526$16,99322 claims
NovartisEntresto$320$15,49722 claims
BayerKerendia$123$12,49715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Westland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →